ZVRA Stock — Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. (ZVRA)

Updated October 16, 2026.

ZVRA is a Stock. Total return is -94.5% over the past 11.5 years, 432.9 points behind SPY at 338.4%.

Zevra Therapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for rare diseases, including Phase 3 candidates for idiopathic hypersomnia, narcolepsy, and vascular Ehlers-Danlos syndrome, as well as marketed products for attention deficit and hyperactivity disorder, urea cycle disorders, and Niemann-Pick disease type C. The company does not currently distribute to shareholders. Zevra Therapeutics appeals to investors seeking exposure to early-stage pharmaceutical development and rare disease treatment, though such companies typically prioritize reinvesting resources into research and clinical advancement rather than returning capital to shareholders.

ZVRA performance versus SPY

Price and return data through 2026-10-16.

Total return is -94.5% over the past 11.5 years, 432.9 points behind SPY at 338.4%. Over the past year its total return — price change plus distributions reinvested — is -12.6%. Its deepest 1-year drawdown was 35.5%.

ZVRA key facts

Asset type

Stock

Asset class

Equity

Inception date

04/16/2015

Distribution frequency

None

Last close

$9.94 (as of 2026-10-16)

Market cap

$590,274,783

Average volume

593882.0

Payment date

12/28/2020

Beta

0.981

Payout ratio

0.0%

P/E ratio

10.8

Forward P/E

10.6724

EPS

$0.92

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ZVRA risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 35.5%.

Who may consider ZVRA — and who may not

It is a weaker fit for investors who need monthly cash flow (ZVRA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ZVRA

• All tickers starting with Z

Tagged: Healthcare.

Frequently asked questions